Dataset Information

Expansion of the CD4⁺ effector T-cell repertoire characterizes peanut-allergic patients with heightened clinical sensitivity.

ABSTRACT:

Background

Individuals with peanut allergy range in clinical sensitivity: some can consume grams of peanut before experiencing any symptoms, whereas others suffer systemic reactions to 10 mg or less. Current diagnostic testing only partially predicts this clinical heterogeneity.

Objective

We sought to identify characteristics of the peanut-specific CD4⁺ T-cell response in peanut-allergic patients that correlate with high clinical sensitivity.

Methods

We studied the T-cell receptor ?-chain (TCR?) usage and phenotypes of peanut-activated, CD154⁺ CD4⁺ memory T cells using fluorescence-activated cell sorting, TCR? sequencing, and RNA-Seq, in reactive and hyporeactive patients who were stratified by clinical sensitivity.

Results

TCR? analysis of the CD154⁺ and CD154^- fractions revealed more than 6000 complementarity determining region 3 sequences and motifs that were significantly enriched in the activated cells and 17% of the sequences were shared between peanut-allergic individuals, suggesting strong convergent selection of peanut-specific clones. These clones were more numerous among the reactive patients, and this expansion was identified within effector, but not regulatory T-cell populations. The transcriptional profile of CD154⁺ T cells in the reactive group skewed toward a polarized T_H2 effector phenotype, and expression of T_H2 cytokines strongly correlated with peanut-specific IgE levels. There were, however, also non-T_H2-related differences in phenotype. Furthermore, the ratio of peanut-specific clones in the effector versus regulatory T-cell compartment, which distinguished the clinical groups, was independent of specific IgE concentration.

Conclusions

Expansion of the peanut-specific effector T-cell repertoire is correlated with clinical sensitivity, and this observation may be useful to inform our assessment of disease phenotype and to monitor disease longitudinally.

SUBMITTER: Ruiter B

PROVIDER: S-EPMC6949413 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Expansion of the CD4<sup>+</sup> effector T-cell repertoire characterizes peanut-allergic patients with heightened clinical sensitivity.

Ruiter Bert B Smith Neal P NP Monian Brinda B Tu Ang A AA Fleming Elizabeth E Virkud Yamini V YV Patil Sarita U SU Whittaker Charles A CA Love J Christopher JC Shreffler Wayne G WG

The Journal of allergy and clinical immunology 20191022 1

<h4>Background</h4>Individuals with peanut allergy range in clinical sensitivity: some can consume grams of peanut before experiencing any symptoms, whereas others suffer systemic reactions to 10 mg or less. Current diagnostic testing only partially predicts this clinical heterogeneity.<h4>Objective</h4>We sought to identify characteristics of the peanut-specific CD4<sup>+</sup> T-cell response in peanut-allergic patients that correlate with high clinical sensitivity.<h4>Methods</h4>We studied t ...[more]

PMID: 31654649

Similar Datasets

Project description:RationaleMicroRNAs (miRNAs) are emerging as important regulators of allergic inflammation and potential therapeutic targets. We sought to identify which miRNAs are expressed in CD4+ T-cells and determine whether allergic stimuli or glucocorticoids alter their expression.MethodsAfter IRB approval, blood was collected from dust mite (DM) allergic rhinitis subjects (n=20), non-allergic controls (n=8), and asthmatics (n=16). Peripheral blood mononuclear cells were incubated with dust mite extract (DME), diluent control, or DME + dexamethasone (0.1 µM). CD4+ T-cells were collected by magnetic bead column, and RNA was isolated by guanidinium/phenol-chloroform extraction. MicroRNA expression was measured using Nanostring microarray and quantitative real time PCR (qPCR).ResultsWe identified 196 miRNAs that were stably expressed in circulating CD4+ T-cells. Allergen stimulation of CD4+ T-cells with DME differentially induced miR-155 expression in cells of DM-allergic subjects as compared to non-allergic subjects. Induction of miR-155 expression was also observed with anti-CD3/anti-CD28 simulation and phorbol-12-Myristate-13-Acetate (PMA) treatment, and further augmented by calcium inophore and bromocyclic AMP in the latter treatment. The level of miR-155 expression was positively associated with expression of the TH2 cytokines IL-5 and IL-13. Inhibition of miR-155 in Jurkat T-cells inhibited the production of these cytokines. Glucocorticoids attenuated the effects of dust mite allergen, raising the possibility that inhibition of this miRNA could be a mechanism through which glucocorticoids exhibit their anti-inflammatory effects. The CD4+ T-cells had a higher level of miR-155 expression in asthma compared to in allergic rhinitis and non-asthmatics. The inhibitory effects of glucocorticoids on CD4+ T-cell miR-155 expression were lost in severe asthmatics.ConclusionMir-155 is differentially expressed in allergic T-cells exposed to DM extract compared to in non-allergic cells and it is inhibited by glucocorticoids. MiR-155 may play a role in mediating allergic inflammation in T-cells and could be an anti-inflammatory target of steroids. This pathway may be de-regulated in severe asthma.